An official website of the United States government
Abstract Colorectal cancer, a significant cause of cancer-related mortality, often exhibits drug resistance, highlighting the need for improved tumor models to advance personalized drug testing and precision therapy. We generated organoids from primary colorectal cancer cells cultured through the conditional reprogramming technique, establishing a framework to perform short-term drug testing studies on patient-derived cells. To model interactions with stromal cells in the tumor microenvironment, we combined cancer cell organoids with carcinoma-associated fibroblasts, a cell type implicated in disease progression and drug resistance. Our organotypic models revealed that carcinoma-associated fibroblasts promote cancer cell proliferation and stemness primarily through hepatocyte growth factor–MET paracrine signaling and activation of cyclin-dependent kinases. Disrupting these tumor–stromal interactions reduced organoid size while limiting oncogenic signals and cancer stemness. Leveraging this tumor model, we identified effective drug combinations targeting colorectal cancer cells and their tumorigenic activities. Our study highlights a path to incorporate patient-derived cells and tumor–stromal interactions into a drug testing workflow that could identify effective therapies for individual patients.
more »
« less
Understanding patient-derived tumor organoid growth through an integrated imaging and mathematical modeling framework
Patient-derived tumor organoids (PDTOs) are novel cellular models that maintain the genetic, phenotypic and structural features of patient tumor tissue and are useful for studying tumorigenesis and drug response. When integrated with advanced 3D imaging and analysis techniques, PDTOs can be used to establish physiologically relevant high-throughput and high-content drug screening platforms that support the development of patient-specific treatment strategies. However, in order to effectively leverage high-throughput PDTO observations for clinical predictions, it is critical to establish a quantitative understanding of the basic properties and variability of organoid growth dynamics. In this work, we introduced an innovative workflow for analyzing and understanding PDTO growth dynamics, by integrating a high-throughput imaging deep learning platform with mathematical modeling, incorporating flexible growth laws and variable dormancy times. We applied the workflow to colon cancer organoids and demonstrated that organoid growth is well-described by the Gompertz model of growth. Our analysis showed significant intrapatient heterogeneity in PDTO growth dynamics, with the initial exponential growth rate of an organoid following a lognormal distribution within each dataset. The level of intrapatient heterogeneity varied between patients, as did organoid growth rates and dormancy times of single seeded cells. Our work contributes to an emerging understanding of the basic growth characteristics of PDTOs, and it highlights the heterogeneity in organoid growth both within and between patients. These results pave the way for further modeling efforts aimed at predicting treatment response dynamics and drug resistance timing.
more »
« less
- Award ID(s):
- 2228034
- PAR ID:
- 10583974
- Editor(s):
- Wodarz, Dominik
- Publisher / Repository:
- PLoS Computational Biology
- Date Published:
- Journal Name:
- PLOS Computational Biology
- Volume:
- 20
- Issue:
- 8
- ISSN:
- 1553-7358
- Page Range / eLocation ID:
- e1012256
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Abstract Background Organoids, which are organs grown in a dish from stem or progenitor cells, model the structure and function of organs and can be used to define molecular events during organ formation, model human disease, assess drug responses, and perform grafting in vivo for regenerative medicine approaches. For therapeutic applications, there is a need for nondestructive methods to identify the differentiation state of unlabeled organoids in response to treatment with growth factors or pharmacologicals. Methods Using complex 3D submandibular salivary gland organoids developed from embryonic progenitor cells, which respond to EGF by proliferating and FGF2 by undergoing branching morphogenesis and proacinar differentiation, we developed Raman confocal microspectroscopy methods to define Raman signatures for each of these organoid states using both fixed and live organoids. Results Three separate quantitative comparisons, Raman spectral features, multivariate analysis, and machine learning, classified distinct organoid differentiation signatures and revealed that the Raman spectral signatures were predictive of organoid phenotype. Conclusions As the organoids were unlabeled, intact, and hydrated at the time of imaging, Raman spectral fingerprints can be used to noninvasively distinguish between different organoid phenotypes for future applications in disease modeling, drug screening, and regenerative medicine.more » « less
-
Abstract BackgroundOropharyngeal cancer (OPC) exhibits varying responses to chemoradiation therapy, making treatment outcome prediction challenging. Traditional imaging‐based methods often fail to capture the spatial heterogeneity within tumors, which influences treatment resistance and disease progression. Advances in modeling techniques allow for more nuanced analysis of this heterogeneity, identifying distinct tumor regions, or habitats, that drive patient outcomes. PurposeTo interrogate the association between treatment‐induced changes in spatial heterogeneity and chemoradiation resistance of oropharyngeal cancer (OPC) based on a novel tumor habitat analysis. MethodsA mathematical model was used to estimate tumor time dynamics of patients with OPC based on the applied analysis of partial differential equations. The position and momentum of each voxel was propagated according to Fokker‐Planck dynamics, that is, a common model in statistical mechanics. The boundary conditions of the Fokker‐Planck equation were solved based on pre‐ and intra‐treatment (i.e., after 2 weeks of therapy)18F‐FDG‐PET SUV images of patients (n = 56) undergoing definitive (chemo)radiation for OPC as part of a previously conducted prospective clinical trial. Tumor‐specific time dynamics, measured based on the solution of the Fokker‐Planck equation, were generated for each patient. Tumor habitats (i.e., non‐overlapping subregions of the primary tumor) were identified by measuring vector similarity in voxel‐level time dynamics through a fuzzy c‐means clustering algorithm. The robustness of our habitat construction method was quantified using a mean silhouette metric to measure intra‐habitat variability. Fifty‐four habitat‐specific radiomic texture features were extracted from pre‐treatment SUV images and normalized by habitat volume. Univariate Kaplan‐Meier analyses were implemented as a feature selection method, where statistically significant features (p < 0.05, log‐rank) were used to construct a multivariate Cox proportional‐hazards model. Parameters from the resulting Cox model were then used to construct a risk score for each patient, based on habitat‐specific radiomic expression. The patient cohort was stratified by median risk score value and association with recurrence‐free survival (RFS) was evaluated via log‐rank tests. ResultsDynamic tumor habitat analysis partitioned the gross disease of each patient into three spatial subregions. Voxels within each habitat suggested differential response rates in different compartments of the tumor. The minimum mean silhouette value was 0.57 and maximum mean silhouette value was 0.8, where values above 0.7 indicated strong intra‐habitat consistency and values between 0.5 and 0.7 indicated reasonable intra‐habitat consistency. Nine radiomic texture features (three GLRLM, two GLCOM, and three GLSZM) and SUVmax were found to be prognostically significant and were used to build the multivariate Cox model. The resulting risk score was associated with RFS (p = 0.032). By contrast, potential confounding factors (primary tumor volume and mean SUV) were not significantly associated with RFS (p = 0.286 andp = 0.231, respectively). ConclusionWe interrogated spatial heterogeneity of oropharyngeal tumors through the application of a novel algorithm to identify spatial habitats on SUV images. Our habitat construction technique was shown to be robust and habitat‐specific feature spaces revealed distinct underlying radiomic expression patterns. Radiomic features were extracted from dynamic habitats and used to build a risk score which demonstrated prognostic value.more » « less
-
Abstract Functional precision medicine offers a promising complement to genomics-based cancer therapy guidance by testing drug efficacy directly on a patient’s tumor cells. Here, we describe a workflow that utilizes single-cell mass measurements with inline brightfield imaging and machine-learning based image classification to broaden the clinical utility of such functional testing for cancer. Using these image-curated mass measurements, we characterize mass response signals for 60 different drugs with various mechanisms of action across twelve different cell types, demonstrating an improved ability to detect response for several slow acting drugs as compared with standard cell viability assays. Furthermore, we use this workflow to assess drug responses for various primary tumor specimen formats including blood, bone marrow, fine needle aspirates (FNA), and malignant fluids, all with reports generated within two days and with results consistent with patient clinical responses. The combination of high-resolution measurement, broad drug and malignancy applicability, and rapid return of results offered by this workflow suggests that it is well-suited to performing clinically relevant functional assessment of cancer drug response.more » « less
-
Glioblastoma (GBM) is highly resistant to treatment and invasion into the surrounding brain is a cancer hallmark that leads to recurrence despite surgical resection. With the emergence of precision medicine, patient-derived 3D systems are considered potentially robust GBM preclinical models. In this study, we screened a library of 22 anti-invasive compounds (i.e., NF-kB, GSK-3-B, COX-2, and tubulin inhibitors) using glioblastoma U-251 MG cell spheroids. We evaluated toxicity and invasion inhibition using a 3D Matrigel invasion assay. We next selected three compounds that inhibited invasion and screened them in patient-derived glioblastoma organoids (GBOs). We developed a platform using available macros for FIJI/ImageJ to quantify invasion from the outer margin of organoids. Our data demonstrated that a high-throughput invasion screening can be done using both an established cell line and patient-derived 3D model systems. Tubulin inhibitor compounds had the best efficacy with U-251 MG cells, however, in ex vivo patient organoids the results were highly variable. Our results indicate that the efficacy of compounds is highly related to patient intra and inter-tumor heterogeneity. These results indicate that such models can be used to evaluate personal oncology therapeutic strategies.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- https://doi.org/10.1371/journal.pcbi.1012256
